drugset / Trial / NCT05364190

Canagliflozin in Patients With Acute Decompansted Heart Failure

NCT05364190

RandomizedParallel-groupOpen-labelTreatment

Summary

The study aims to investigate the efficacy and safety of the early initiation of canagliflozin treatment in hospitalized heart failure patients with volume overload (warm-wet) who require the use of I.V loop diuretic during the hospitalization period.

Timeline

Start
2022-06-04
Primary completion
2023-12-01
Completion
2024-03-01

Drugs

EvaluationDrugModalityDoseRoute
Subject CANAGLIFLOZIN ANHYDROUS Small molecule 100 mg
Comparator Empagliflozin Small molecule 10 mg